

# Assessment of Thyroid Profile (TSH, T3 and T4) of HIV Positive Subjects Visiting Central Hospital, Benin City, Edo State

## Abstract

Human Immunodeficiency Virus (HIV) infection is caused by human immunodeficiency virus, a lentivirus within the family. Thyroid hormones regulate the basal metabolic rate of hepatocytes, and thereby modulate hepatic function; low total and free T3 levels may be regarded as an adaptive hypothyroid state that serves to reduce the basal metabolic rate within hepatocytes and preserve liver function and total body protein stores. The aim of this study is to evaluate the thyroid profile (TSH, T3 and T4) of HIV positive subjects visiting Central Hospital in Benin City, Edo State. The subjects in this study comprise of HIV positive volunteers aged between 18 to 50 years attending Central Hospital Benin City, Edo State, Nigeria. A total of one hundred and twenty (120) subjects were recruited for this study. The study comprises of eighty (80) HIV positive subjects (test samples) and forty (40) apparently healthy subjects (controls). This study was designed as a prospective and cross-sectional study to evaluate the thyroid profile (TSH, T3 and T4) of HIV positive subjects visiting Central Hospital in Benin city, Edo State, Nigeria. HIV serostatus was determined according to centre for disease and prevention (CDC – UMD). Plasma total TSH, T<sub>4</sub> & T<sub>3</sub> was quantitatively determined using enzyme immunoassay. The result showed that TSH levels were significantly higher ( $p < 0.05$ ) in subjects ( $2.75 \pm 1.59$  mIU/ml) when compared with the control ( $1.92 \pm 1.11$  mIU/ml). On the contrary, T<sub>3</sub> levels were not significantly lower ( $p > 0.05$ ) in subjects ( $1.32 \pm 0.63$  ng/ml) when compared with the control ( $1.49 \pm 0.35$  ng/ml). T<sub>4</sub> levels were significantly lower ( $p < 0.05$ ) in subjects ( $6.06 \pm 1.83$  µg/dl) when compared with the control ( $7.09 \pm 1.78$  µg/dl). The results showed a significant non-increased in TSH ( $p > 0.05$ ) in subjects who had been on drugs within 11-15 years, when compared with subjects who have been on drugs for a period of 0-5 months, 1-5 years, 6-10 years and 16-20 years. T<sub>3</sub> levels were higher ( $p > 0.05$ ) in subjects who had been on drugs within 16-20 years, when compared with subjects who have been on drugs for a period of 0-5 months, 1-5 years, 6-10 years and 11-15 years. T<sub>4</sub> levels were higher ( $p > 0.05$ ) in subjects who had been on drugs within 16-20 years, when compared with subjects who have been on drugs for a period of 0-5 months, 1-5 years, 6-10 years and 11-15 years. In conclusion, this study highlights that TSH levels were significantly higher ( $p < 0.05$ ) in subjects when compared with the control, and T<sub>4</sub> levels were significantly lower ( $p < 0.05$ ) in subjects when compared with the control. Larger studies are needed to examine the epidemiology and health consequences of mild thyroid dysfunction in HIV-infected subjects and to better inform screening and treatment guidelines.

**Keywords: Thyroid Profile, TSH, T3, T4, HIV**

## 1. INTRODUCTION

Human Immunodeficiency Virus (HIV) infection is caused by human immunodeficiency virus, a lentivirus within the family Retroviridae (Prescott, Harley, & Klein, 2019). It causes progressive impairment of the body's cellular immune system leading to increased susceptibility to infection and tumors and the fatal condition Acquired Immune Deficiency syndrome, (AIDS) [1]. Acquired Immunodeficiency Syndrome (AIDS) was recognized as an emerging disease only in early 1980, but has rapidly established itself throughout the world, and likely to endure and persist well in 21<sup>st</sup> century. AIDS has evolved from a mysterious illness to a global pandemic which has infected tens of millions in less than 20 years period [2].

Total number of HIV-AIDS in world is continuously rising. According to UNAIDS 2018 data 37.9 million people (out of these, 2.1 million are Children under 15 years) are living with HIV/AIDS worldwide, the vast majority of whom are in low- and middle-income countries, out of these only 24.5 million people were assessing antiretroviral therapy [3]. India has the third largest HIV epidemic in the world, 2.1 million people living with HIV in 2015. In India, HIV epidemic shifts from high-risk group to bridge population and then to general population. In 2017, 79% of people lining with HIV were aware of their status of whom only 56% were on ART [3]. Increasing experience with this syndrome has led to the recognition of a variety of HIV related endocrine disorder that occurs during both the early and late stages of the disease. Among these disorders a high prevalence of abnormalities in thyroid function tests is reported in previous cross-sectional studies. Unique abnormalities of thyroid function tests were reported by Lambert et al, [4]. They described a progressive elevation in serum thyroxin binding globulin (sr.TBG) but not in other binding proteins such as cortisol binding globulin (CBG) that accompanies a decline in CD4+ count with advancing HIV infection. Feldt-Rasmussen et al, [5] reported elevation of sr. TSH and s. TBG concentration in conjunction with low FT-4 that occurs frequently and correlates with CD4+ cell depletion in AIDS patients. In addition, this thyroid dysfunction correlated with the degree of immunosuppression and viral replication and preceded the worsening of the disease. Subtle alterations in thyroid function tests (TFT) are more common in HIV infection and are sometimes already detectable in the early phase of disease. The changes in thyroid function tests are HIV specific and are consistent with an abnormal response to acute illness. Various mechanisms have been proposed to explain such abnormalities in TFT [6]. These include direct infection of thyroid gland by opportunistic organisms such as *Pneumocystis carinii*, infiltration of the gland by tumors such as Kaposi sarcoma, effect of humoral factors such as IL-1 $\alpha$  and TNF- $\alpha$ , side effect of the drugs used in the course of HIV infection for e.g. rifampicin, ketoconazole, steroids etc. and direct infection of gland by HIV.

There are three groups of enzymes that regulate thyroid hormone metabolism, forming part of the iodothyronine seleno-deiodinase enzyme system, Type 1 = D1 (deiodinase 1), Type 2 = D2 (deiodinase 2) and Type 3 = D3 (deiodinase 3). They are responsible for the activation of T4 to T3, inactivation of T4 to rT3 and the conversion of rT3 and T3 to T2.3 The type 1 deiodinase is mainly found in the liver and kidney and accounts for approximately 30–40% of extra thyroidal production of T3 (12 nmol). Type 3 deiodinase system primarily exhibits inner-ring deiodination. It is found in the liver, skin and CNS, where it catalyses the conversion of T4 to rT3 and T3 to T2, both inactive metabolites; it also converts rT3 to T2. The patients with cirrhosis have low total and fT3 and an elevated rT3, probably reflecting a reduced deiodinase type 1 activity, resulting in reduced conversion of T4 to T3. This results in an increase in conversion of T4 to rT3 by the deiodinase type 3 systems, and an increase in the rT3 to T3 ratio [7]. The level of thyroid hormones is also important for normal hepatic function and bilirubin metabolism. Thyroid hormones regulate the basal metabolic rate of hepatocytes, and thereby modulate hepatic function; low total and free T3 levels may be regarded as an adaptive hypothyroid state that serves to reduce the basal metabolic rate within hepatocytes and preserve liver function and total body protein stores [8]. In experimental animal, thyrotoxicosis is associated with an increase bilirubin output in bile, which may result from increase degradation of hepatic heme [9]. Thyroid induced alterations in hepatic metabolism of bilirubin, specifically a decrease in glucuronyltransferase, may be responsible for clinical occurrence of unconjugated hyperbilirubinemia, possibly by masking previously unorganized Gilbert's syndrome. Thyroid hormone decreases bile acid production and total bile acid pool size [10]. Liver on the other hand metabolizes the thyroid hormones and regulates their systemic endocrine effects. Conceivably, the disorders of these two organs would interact or influence each other. The derangements in thyroid profile in liver patients have been well documented in English literature. The plasma T3:rT3 ratio has a negative correlation with the severity of cirrhosis when assessed in non-alcoholic cirrhosis. In patients with acute hepatitis of mild or moderate severity, there is

elevated serum levels of total T4, due to increased thyroid-binding globulin, which is synthesized as an acute-phase reactant, but normal levels of free T4. In cirrhosis total and fT3 are found to be low, probably reflecting a reduced deiodinase type 1 activity, resulting in reduced conversion of T4 to T3 [10].

The human immunodeficiency virus (HIV) has thus far infected over 22.4 million people in sub-Saharan Africa and Nigeria remains the country with the third highest number of HIV-infected subjects in the world [11]. Since HAART was introduced in the mid-1990s, as a treatment for HIV/AIDS, the morbidity and mortality associated with HIV/AIDS has reduced considerably. According to the 2015 HIV Sentinel Survey and National HIV Prevalence AIDS Estimates Reports, an estimated 645,810 HIV-infected Nigerians would have been requiring ART by 2010 [12]. HAART regimens typically include a combination of at least three drugs, such as different association of protease inhibitors (PI), non-nucleoside reverse transcriptase inhibitors (NNRTI) and nucleoside reverse transcriptase inhibitors (NRTI). HAART however, has been reported to be associated with a number of side effects in HIV/AIDS subjects among which dyslipidaemia and lipodystrophy are common metabolic disorders with increased risk of cardiovascular diseases and diabetes in the HIV-infected subjects [13-16]. Studies have also shown that HAART treatment, especially those including protease inhibitors, is associated with hypertriglyceridaemia, hypercholesterolaemia, hypo HDL-cholesterolaemia and hyperinsulinaemia [17-20].

Although thyroid function tests are often abnormal in HIV patients, the prevalence of overt thyroid disorder is not significantly different from that of the general population. Most asymptomatic patients with HIV infection have normal thyroid function. Some, however, exhibit increased serum T4 and T3 concentrations. These increases are as a result of increases in serum thyroxine-binding globulin, the cause of which is unknown. However, with progression of HIV infection and as the patients become more ill, serum T4 and T3 concentrations decline, as is obtained in most if not all chronically ill patients; serum thyrotropin concentrations however remain normal or slightly depressed. These changes are as a result of reduction in serum binding proteins, decreased extra thyroidal conversion of T4 to T3, and decreased secretion of thyrotropin. Cytokines may be involved in some of these; especially the reduction in the peripheral conversion of T4 to T3.

The abnormalities of thyroid function that have been identified among patients infected with HIV include: overt hypothyroidism, subclinical hypothyroidism, Graves' disease, subclinical hyperthyroidism, Isolated low free T4 (FT4), Isolated low free T3 (FT3), acute suppurative thyroiditis, and sick euthyroid syndrome (non-thyroidal illness). Thyroid hormones are crucial for optimal function of the immune system [21]. A study conducted in southern Nigeria found that seropositive subjects who progressed to clinical AIDS, were more likely to be hypothyroid while HIV negative subjects were more likely to have normal or abnormally high thyroid hormone levels [22]. This was similar to a finding of lower thyroid hormone levels in HIV positive patients compared to HIV negative controls in another study [23]. A study carried out by Unachukwu et al. [24] in southeast Nigeria, found the prevalence of sick euthyroid syndrome and subclinical hypothyroidism to be 48% and 3.5-12.2% respectively among patients with advanced AIDS.

Thyroid dysfunction reduces the quality of life of patients infected with HIV. Changes in pituitary-thyroid function occur in patients with virtually all illnesses and those undergoing major surgical procedures. Although such changes are referred to as the euthyroid sick syndrome, the key changes namely; decreases in serum triiodothyronine and thyroxine concentrations have multiple causes, vary considerably in different patients, and very likely have different effects on different tissues [25]. Although it is generally assumed that the decreases have no pathophysiologic consequences, it is by no means clear that the patients are in fact euthyroid.

Overt hypothyroidism leads to the insidious onset of fatigue, weakness, dry skin, cold intolerance, slowed mentation, constipation, hoarse voice, paresthesia, bradycardia, and delayed relaxation of tendon reflexes. Overt hyperthyroidism is characterized by irritability, heat intolerance, sweating, warm moist skin, palpitations, tachycardia, fatigue, weight loss with increased appetite, diarrhea, tremor, muscle weakness, hyperreflexia, and lid retraction. The consequences of subclinical hyperthyroidism include reduced bone mineral density and an increased risk of atrial fibrillation, the risk of which is proportional to the degree of thyroid hyperfunction [26]. Furthermore, subclinical hyperthyroidism may precede overt hyperthyroidism [27]. It is unclear why HIV-infected patients are susceptible to thyroid dysfunction, but HIV infection is regarded as a crucial factor. Furthermore, the influence of HIV infection on thyroid function changes with the course of the disease. Asymptomatic, subtle abnormalities of thyroid function tests have been described in a small minority of patients with stable HIV infection [28-30]. With the progression of the disease, a pattern of sick euthyroid syndrome may develop. The most frequent abnormalities in thyroid function tests are those associated with subclinical hypothyroidism [26-28, 31, 32]. An increasing number of patients taking anti-HIV drugs are presenting with thyroid disorders as a result of improved immune function (immune reconstitution syndrome). Graves' disease is the commonest among immune reconstitution syndromes; others include Hashimoto's thyroiditis and hypothyroidism. Autoimmune Thyroid disease (AITD) occurs in 3% of women and 0.2% of men. Goddard & Shoenfeld [33] proposed a staging of autoimmune manifestations related to HIV/AIDS.

Asymptomatic subtle abnormalities of thyroid function tests, such as low serum levels of only T4, have been described in a small percentage of patients with stable HIV infection by some authors [29, 30] but most asymptomatic patients with early HIV infection and stable body weight have had normal T3 and T4 levels, as well as low reverse triiodothyronine (rT3) and often high thyroid binding globulin (TBG) values [28]. Moreover, low T3 and FT3 levels associated with low rT3 and high TBG levels have been found in other groups of patients in relation to the worsening of HIV illness when anorexia and weight loss occur, as happens in a classic sick euthyroid syndrome which, unlike the HIV condition, is usually characterised by high rT3 levels as a result of its decreased clearance [34].

The most common change is a decrease in extrathyroidal conversion of thyroxine (T4) to triiodothyronine (T3), the active form of thyroid hormone. This reaction is responsible for the production of 75 to 80 percent of the circulating triiodothyronine in normal subjects and probably more of the intracellular triiodothyronine [35]. In illness, the production and serum concentrations of triiodothyronine decrease as a result either of decreased delivery of thyroxine to the widely distributed intracellular deiodinases that catalyze the conversion or of decreases in the activity of the enzymes [36]. A second change is a decrease in thyrotropin releasing hormone (TRH) secretion, which causes decreased TSH secretion and, in time, decreases serum thyroxine concentrations and further decrease in serum triiodothyronine concentrations; the latter due both to decreased thyroid secretion of triiodothyronine and decreased availability of thyroxine for peripheral conversion to triiodothyronine [37, 38]. We hereby perform this research to evaluate the thyroid profile (TSH, T3 and T4) of HIV positive subjects in Benin City, Edo State.

## **2. MATERIALS AND METHODS**

### **Area of Study**

This study was carried out in Benin-City, Edo State. Benin City is a city with year 2006 estimated population of 1,147,188 and the capital of Edo State in southern Nigeria. It is a city approximately 25 miles north of the Benin River. It is situated 200 miles by road east of Lagos. Benin is the centre of Nigeria's rubber industry, but processing palm nuts for oil is also an important traditional industry. Benin City is situated at 6.34° North latitude, 5.63° East longitude and 80 meters elevation above the sea level [39].

### Study Population

The subjects in this study comprise of HIV positive volunteers aged between 18 to 50 years attending Central Hospital Ekpoma, Edo State, Nigeria. A total of one hundred (100) subjects were recruited for this study. The sample size (N) is calculated from the formula below using prevalence from previous studies. The prevalence of 3.4% of HIV subjects in Edo state was from the study conducted by Onovo *et al.*, [40]

Sample size (N) =  $\frac{Z^2 P q}{d^2}$ , where

N = the desired size

Z = 1.96 (standard score)

P = Prevalence (3.4%) (0.034)

q. = 1- P (0.966)

d = sample error tolerated (0.05)

$$N = \frac{1.96^2 \times 0.034 \times 0.966}{0.05^2} = 50.5 \text{ approximately} = 51$$

The sample size was upgraded to 80 due to 50% attrition of the original sample size. The study was conducted on 120 subjects comprising of forty (40) apparently healthy subjects (controls) and eighty (80) HIV positive subjects (test samples).

### Research Design

This study was designed as a prospective and cross-sectional study to evaluate the thyroid profile (TSH, T3 and T4) of HIV positive subjects in Benin city, Edo State, Nigeria. A complete record of medical history (age, gender and other important medical information) was obtained for each subject from the patient's medical records. This study was carried out within six (6) months. Furthermore, in order to ensure HIV status validity, both confirmed and negative cases were re-tested by the researcher with HIV test strips using standard Laboratory procedures. It is on the basis of this validity that HIV positive and control subjects were selected and grouped for the study. The results of the thyroid profile (TSH, T3 and T4) obtained for the HIV positive subjects obtained were compared with that of the control using statistical methods.

### Sample Collection

Five millilitres (5mls) of venous blood sample were collected from each subject from the ante-cubital vein using sterile disposable syringe. The blood samples were immediately placed in a labelled lithium heparin and EDTA containers for both subjects and control individuals for the estimation of thyroid profile (TSH, T3 and T4) and some micronutrients (Selenium, Copper, and Zinc). The blood was spun for 10 minutes at 5000 rpm. The serum was separated from the red cells using a dry clean Pasteur pipette into dry clean plain specimen containers which was labelled corresponding to the initial blood samples containers. The serum was then stored at -20°C pending the analysis of the samples.

### Sample Analysis

#### HIV Serology Test

HIV serostatus was determined according to centre for disease and prevention (CDC – UMD). HIV rapid testing serial algorithm II guideline [41]. Determine HIV – ½ kit, an immunochromatographic technique, was the kit used. Positive results by “Determine HIVI/II” kit (Alere Medical Co., Ltd., Chiba, Japan) was confirmed with “Unigold HIVI/II” test kit (Trinity Biotech Plc., Bray, Ireland) while negative results by “Determine HIVI/II” ended testing. Discordant results are repeated and finally tested with a tie-breaker kit-statpak. Final results were considered positive or negative on the basis of tie-breaker result.

### **Determine HIVI/II Test**

**Principle:** Alere Determine HIVI/II is an immunochromatographic test for the qualitative detection of antibodies to HIV I/II. Sample is added to the sample pad. As the sample migrates through the conjugate pad, it reconstitutes and mixes with the selenium colloid-antigen conjugate. This mixture continues to migrate through the solid phase to the immobilized recombinant antigens and synthetic peptides at the patient window site. If antibodies to HIV -1 and/or HIVII are present in the sample, the antibodies bind to the antigen-selenium colloid and to the antigen at the patient window, forming a red line at the patient window site. If antibodies to HIVI/II and /or HIVII are absent, the antigen-selenium colloid flows past the patient window, and no red line is formed at the patient window site. To ensure assay validity, a procedural control bar is incorporated in the assay device [41].

### **UNIGOLD HIVI/II Test**

**Principle:** HIV is a rapid immunoassay based on the immunochromatographic sandwich principle. Recombinant proteins representing the immunodominant regions of the envelope proteins of HIVI/II and HIVII, glycoprotein gp41, gp120 (HIVI/II) and glycoprotein gp36 (HIVII) respectively, are immobilized at the test region of the nitrocellulose strip. These proteins are also linked to colloidal gold and impregnated below the test region of the device. A narrow band of the nitrocellulose membrane is also sensitized as a control region [41].

**Determination of Total T<sub>3</sub> Concentration:** Plasma total T<sub>3</sub> was quantitatively determined using enzyme immunoassay [42].

**Principle:** In the T<sub>3</sub> EIA, a second antibody (goat anti-mouse IgG) is coated on microtiter wells. measured amount of patient serum, a certain amount of mouse monoclonal anti-T<sub>3</sub> antibody, and a constant amount of T<sub>3</sub> conjugated with horseradish peroxidase are added to the microtiter wells. During incubation, the mouse anti-T<sub>3</sub> antibody is bound to the second antibody on the wells, and T<sub>3</sub> and conjugated T<sub>3</sub> compete for the limited binding sites on the anti-T<sub>3</sub> antibody. After a 60-minute incubation at room temperature, the wells are washed 5 times by water to remove unbound T<sub>3</sub> conjugate. A solution of TMB Reagent is then added and incubated for 20 minutes, resulting in the development of blue color. The color development is stopped with the addition of Stop Solution, and the absorbance is measured spectrophotometrically at 450nm. The intensity of the color formed is proportional to the amount of enzyme present and is inversely related to the amount of unlabeled T<sub>3</sub> standards assayed in the same way, the concentration of T<sub>3</sub> in the unknown sample is then calculated [42].

**Determination of Total T<sub>4</sub> Concentration:** Plasma Thyroxin (T<sub>4</sub>) level was determined using Enzyme immuno assay (EIA) [42].

**Principle:** To measure T<sub>4</sub> by competitive immunoassay techniques, a sample of serum or plasma containing the T<sub>4</sub> to be quantified is mixed with labeled T<sub>4</sub> and T<sub>4</sub> antibody. The labeled T<sub>4</sub> contains 8-anilino-1-naphthalene sulfonic acid (ANS) to inhibit binding of T<sub>4</sub> to serum proteins, which would otherwise interfere with the assay. During incubation, a fixed amount of labeled T<sub>4</sub> competes with the unlabeled T<sub>4</sub> in the sample, standard, or quality control serum for a fixed number of binding sites on the specific T<sub>4</sub> antibody. Separation of the unbound T<sub>4</sub> from antibody-bound T<sub>4</sub> and the subsequent measurement of the labeled fraction of the bound phase completes the test. By comparing results of the unknown sample with those obtained from a series of T<sub>4</sub> calibrators, an accurate measurement of the T<sub>4</sub> concentration in the sample can be obtained [42].

**Determination of Thyroid Stimulating Hormone:** Plasma Thyroid stimulating Hormone (TSH) was quantitatively determined using ELISA.

**Principle:** The TSH ELISA test is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay system utilizes a unique monoclonal antibody directed against a distinct antigenic determinant on the intact TSH molecule. Mouse monoclonal anti-TSH antibody is used for solid phase immobilization (on the microtiter wells). A goat anti-TSH antibody is in the antibody-enzyme (horseradish peroxidase) conjugate solution. The test sample is allowed to react simultaneously with the two antibodies, resulting in the TSH molecules being sandwiched between the solid phase and enzyme-linked antibodies. After a 60-minute incubation at room temperature, the wells are washed with water to remove unbound labeled antibodies. A solution of TMB Reagent is added and incubated for 20 minutes, resulting in the development of a blue color. The color development is stopped with the addition of Stop Solution, changing the color to yellow. The concentration of TSH is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450 nm.

**Guidelines for detection of thyroid dysfunction**

- i. Normal function: T3, T4 and TSH within normal range.
- ii. Primary hypothyroidism: TSH more than 8.1mIU/ml; T3 and T4 less than the normal values.
- iii. Secondary hypothyroidism: T3 and T4 less than normal values; TSH is within normal.
- iv. Subclinical hypothyroidism: TSH more than 8.1mIU/ml; T3 and T4 within normal range.
- v. Primary hyperthyroidism: TSH less than or equal 0.2; T3 and T4 more than normal values.
- vi. Secondary hyperthyroidism: T3 and T4 more than the normal value; TSH within normal.
- vii. Subclinical hyperthyroidism: TSH less than the normal values; T3 and T4 within normal [43].

**Data Analysis**

The Mean and standard deviation of the results obtained was calculated. ANOVA (LSD) was used for the analysis using SPSS package version 21. Values with  $p < 0.05$  shall be considered statistically significant in this study.

**3. RESULTS**

**Socio-Demographic Characteristics of the Study Population**

Table 1 revealed the socio-demographic characteristics of the study population. The subjects were categorized into five age groups; 16-25 years; 26-35 years; 36-45 years; 46-55 years and 56-65 years. The result for age showed that majority of the subjects were within the age range of 36-45 years accounting for 33.8%, followed by 46-55 years 23.8%, 26-35 years 18.8%, 16-25 years 15.0% and 56-65 years being the least accounted for 8.8%. The Age (Mean  $\pm$ SD) of the subjects was (39.34 $\pm$ 11.76). With respect to gender, 27.5% of the subjects were male and 72.5% of the subjects were female. Based on duration of drugs, 8.8% of the subjects have been on drugs within the period of 0-11months, 1-5years 33.8%, 6-10years 32.5%, 11-15years 18.8% and 16-20years 6.3%.

**Table .1: Socio-Demographic Characteristics of the Study Population (n=120)**

Variables	Frequency	Percentage (%)	
<b>Age (Years)</b>	16-25	12	15.0
	26-35	15	18.8
	36-45	27	33.8
	46-55	19	23.8
	56-65	7	8.8
<b>Age (Mean <math>\pm</math>SD)</b>		39.34 $\pm$ 11.76	

<b>Gender</b>	Male	22	27.5	
	Female	58	72.5	
<b>Duration of drugs</b>	0-11months	7	8.8	
	1-5years	27	33.8	
	6-10years	26	32.5	
<b>Parameters</b>	<b>Control (n=40)</b>	<b>Subjects (n=80)</b>	<b>t value</b>	<b>P value</b>
<b>TSH (miu/L)</b>	1.92±1.11	2.75±1.59	2.967	0.004
<b>T<sub>3</sub> (ng/L)</b>	1.49±0.35	1.32±0.63	1.560	0.121
<b>T<sub>4</sub> (ng/L)</b>	7.09±1.78	6.06±1.83	2.913	0.004

### TSH, T<sub>3</sub> and T<sub>4</sub> levels between Subjects and Control

The results in table 2 showed the comparison of TSH, T<sub>3</sub> and T<sub>4</sub> levels between the subjects and control. The result showed that TSH levels were significantly higher ( $p < 0.05$ ) in subjects ( $2.75 \pm 1.59$  miu/L) when compared with the control ( $1.92 \pm 1.11$  miu/L). On the contrary, T<sub>3</sub> levels were also not significantly lower ( $p > 0.05$ ) in subjects ( $1.32 \pm 0.63$  ng/L) when compared with the control ( $1.49 \pm 0.35$  ng/L). T<sub>4</sub> levels were significantly lower ( $p < 0.05$ ) in subjects ( $6.06 \pm 1.83$  ng/L) when compared with the control ( $7.09 \pm 1.78$  ng/L).

**Table 2: TSH, T<sub>3</sub> and T<sub>4</sub> levels between subjects and control**

**KEY: n=Sample size ;  $p > 0.05$ = Not significant;  $p < 0.05$ = Significant**

Parameters	Male Control (n=21)	Male Subjects (n=22)	t value	P value
<b>TSH (miu/L)</b>	2.32±1.23	2.59±1.58	0.619	0.539
<b>T<sub>3</sub> (ng/L)</b>	1.54±0.38	1.33±0.65	1.279	0.208
<b>T<sub>4</sub> (ng/L)</b>	6.58±1.70	6.27±1.88	0.571	0.571

### TSH, T<sub>3</sub> and T<sub>4</sub> levels between Male Subjects and Male Control

The results in table 3 showed the comparison of TSH, T<sub>3</sub> and T<sub>4</sub> levels between the male subjects and control. The result showed that TSH levels were not significantly higher ( $p > 0.05$ ) in male subjects ( $2.59 \pm 1.58$  miu/L) when compared with the control ( $2.32 \pm 1.23$  miu/L). T<sub>3</sub> levels were not significantly lower ( $p > 0.05$ ) in male subjects ( $1.33 \pm 0.65$  ng/L) when compared with the control ( $1.54 \pm 0.38$  ng/L). T<sub>4</sub> levels were also not significantly lower ( $p > 0.05$ ) in male subjects ( $6.27 \pm 1.88$  ng/L) when compared with the control ( $6.58 \pm 1.70$  ng/L).

**Table 3: TSH, T<sub>3</sub> and T<sub>4</sub> levels between male subjects and male control**

**KEY: n=Sample size ;  $p > 0.05$ = Not significant;  $p < 0.05$ = Significant**

### TSH, T<sub>3</sub> and T<sub>4</sub> levels between Female Subjects and Female Control

The results in table 4 showed the comparison of TSH, T<sub>3</sub> and T<sub>4</sub> levels between the female subjects and control. The result showed that TSH levels were significantly higher ( $p < 0.05$ ) in female subjects ( $2.81 \pm 1.60$  miu/L) when compared with the control ( $1.47 \pm 0.76$  miu/L). On the contrary, T<sub>3</sub> levels were not significantly lower ( $p > 0.05$ ) in female subjects ( $1.32 \pm 0.64$  ng/L) when compared with the control

(1.44±0.32 ng/ L). T<sub>4</sub> levels were significantly lower (p<0.05) in female subjects (5.98±1.83 ng/L) when compared with the control (7.65±1.75 ng/L).

**Table 4: TSH, T<sub>3</sub> and T<sub>4</sub> between female subjects and female control**  
**KEY: n=Sample size ; p>0.05= Not significant; p<0.05= Significant**

**TSH, T<sub>3</sub> and T<sub>4</sub> levels of the Subjects with respect to Gender**

Parameters	Male Subjects (n=22)	Female Subjects (n=58)	t value	P value
TSH (miu/L)	2.59±1.58	2.81±1.60	0.557	0.579
T <sub>3</sub> (ng/L)	1.33±0.65	1.32±0.64	0.063	0.950
T <sub>4</sub> (ng/L)	6.27±1.88	5.98±1.83	0.615	0.540

The results in table 5 showed the comparison of TSH, T<sub>3</sub> and T<sub>4</sub> levels of the subjects with respect to gender. The result showed that TSH levels were not significantly lower (p>0.05) in male subjects (2.59±1.58 miu/ L) when compared with the female subjects (2.81±1.60 miu/ L). T<sub>3</sub> levels were not significantly higher (p>0.05) in male subjects (1.33±0.65 ng/ L) when compared with the female subjects (1.32±0.64 ng/ L). T<sub>4</sub> levels were also not significantly higher (p>0.05) in male subjects (6.27±1.88 ng/ L) when compared with the female subjects (5.98±1.83 ng/ L).

**Table 5: TSH, T<sub>3</sub> and T<sub>4</sub> levels of subjects with respect to gender**  
**KEY: n=Sample size; p>0.05= Not significant; p<0.05= Significant**

**TSH, T<sub>3</sub> and T<sub>4</sub> levels of the Subjects according to Age**

The results in table 6 showed the comparison of TSH, T<sub>3</sub> and T<sub>4</sub> levels of the subjects according to age. The results showed a significant non-increased in TSH (p>0.05) in subjects aged 16-25 years (3.04±1.26 miu/L) when compared with subjects within the age range of 46-55 years (3.01±1.92 miu/L), 36-45 years

Parameters	16-25 Years (n=21)	26-35 Years (n=29)	36-45 Years (n=26)	46-55 Years (n=23)	56-65 Years (n=11)	F value	P value
TSH (miu/L)	3.04±1.26 <sup>a</sup>	2.03±1.39 <sup>a</sup>	2.95±1.69 <sup>a</sup>	3.01±1.92 <sup>a</sup>	2.30±0.49 <sup>a</sup>	1.255	0.295
T <sub>3</sub> (ng/L)	1.25±0.55 <sup>a</sup>	1.69±0.73 <sup>a</sup>	1.21±0.53 <sup>ab</sup>	1.24±0.67 <sup>ab</sup>	1.31±0.68 <sup>a</sup>	1.645	0.172
T <sub>4</sub> (ng/L)	5.22±1.24 <sup>a</sup>	7.10±1.80 <sup>b</sup>	5.83±1.83 <sup>a</sup>	6.04±1.88 <sup>ab</sup>	6.13±2.01 <sup>ab</sup>	2.226	0.074

(2.95±1.69 miu/L), 56-65 years (2.30±0.49 miu/L) and 26-35 years (2.03±1.39 miu/L). T<sub>3</sub> levels were higher (p>0.05) within the age range of 26-35 years (1.69±0.73 ng/L) when compared with 56-65 years (1.31±0.68 ng/L), 16-25 years (1.25±0.55 ng/L), 46-55 years (1.24±0.67 ng/L) and 36-45 years (1.21±0.53 ng/L). T<sub>4</sub> levels were higher within the age range of 26-35 years (7.10±1.80 ng/L) when compared with 56-

Parameters	Female Control (n=19)	Female Subjects (n=58)	t value	P value
TSH (miu/L)	1.47±0.76	2.81±1.60	3.502	0.001
T <sub>3</sub> (ng/L)	1.44±0.32	1.32±0.64	0.771	0.443
T <sub>4</sub> (ng/L)	7.65±1.75	5.98±1.83	3.481	0.001

65 years (6.13±2.01 ng/L), 45-55 years (6.04±1.88 ng/L), 36-45 years (5.83±1.83 ng/L) and 16-25 years (5.22±1.24 ng/L).

**Table 6: TSH, T<sub>3</sub> and T<sub>4</sub> levels of the subjects according to age**

Parameters	0-11 Months (n=21)	1-5 Years (n=29)	6-10 Years (n=26)	11-15 Years (n=23)	16-20 Years (n=11)	F value	P value
TSH (miu/L)	2.75±1.25 <sup>a</sup>	2.83±1.73 <sup>a</sup>	2.56±1.37 <sup>a</sup>	3.33±1.86 <sup>a</sup>	1.53±0.78 <sup>ab</sup>	1.370	0.253
T <sub>3</sub> (ng/L)	1.36±0.63 <sup>a</sup>	1.20±0.71 <sup>a</sup>	1.39±0.58 <sup>a</sup>	1.27±0.65 <sup>a</sup>	1.74±0.31 <sup>a</sup>	0.884	0.478
T <sub>4</sub> (ng/L)	5.34±2.61 <sup>a</sup>	5.83±1.74 <sup>a</sup>	6.26±1.65 <sup>a</sup>	6.28±1.73 <sup>a</sup>	6.60±2.63 <sup>a</sup>	0.609	0.658

**KEY: n=Sample size; p>0.05= Not significant; p<0.05= Significant**

**Values in a row with the same superscript are not significantly different at p<0.05**

#### **TSH, T<sub>3</sub> and T<sub>4</sub> levels of the Subjects according to Duration of Drugs.**

The results in table 7 showed the comparison of TSH, T<sub>3</sub> and T<sub>4</sub> levels of the subjects according to duration of drugs. The results showed a significant non increased in TSH (p>0.05) in subjects who had been on drugs within 11-15years, when compared with subjects who have been on drugs for a period of 0-5 months, 1-5 years, 6-10 years and 16-20 years. T<sub>3</sub> levels were higher (p>0.05) in subjects who had been on drugs within 16-20 years, when compared with subjects who have been on drugs for a period of 0-5 months, 1-5 years, 6-10 years and 11-15 years. T<sub>4</sub> levels were higher (p>0.05) in subjects who had been on drugs within 16-20 years, when compared with subjects who have been on drugs for a period of 0-5 months, 1-5 years, 6-10 years and 11-15 years.

**Table 7: TSH, T<sub>3</sub> and T<sub>4</sub> levels of the subjects according to duration of drugs**

**KEY: n=Sample size; p>0.05= Not significant; p<0.05= Significant**

**Values in a row with the same superscript are not significantly different at p<0.05**

#### **4. DISCUSSION**

The study aims at evaluating the thyroid profile (TSH, T<sub>3</sub> and T<sub>4</sub>) of HIV positive subjects visiting Central Hospital in Benin City, Edo State. In our study majority of the subjects were within the age range of 36-45 years accounting for 33.8%, followed by 46-55 years 23.8%, 26-35 years 18.8%, 16-25 years 15.0% and 56-65 years being the least accounted for 8.8%. The Age (Mean ±SD) of the subjects was (39.34±11.76). This is in agreement with the study of Shukla et al [44] in which majority of the cases (81.45%) were between 20-45 years and Michèle et al [45] in which mean age was 40.8 years (SD = 9.54). The mean age of participants were similar to that observed in previous studies [23, 46, 47].

With respect to gender, 27.5% of the subjects were male and 72.5% of the subjects were female. Based on duration of drugs, 8.8% of the subjects have been on drugs within the period of 0-11months, 1-5years 33.8%, 6-10years 32.5%, 11-15years 18.8% and 16-20years 6.3%. The result from this study showed that TSH levels were significantly higher (p<0.05) in subjects (2.75±1.59 miu/L) when compared with the control (1.92±1.11 miu/L). On the contrary, T<sub>3</sub> levels were also not significantly lower (p>0.05) in subjects (1.32±0.63 ng/L) when compared with the control (1.49±0.35 ng/L). T<sub>4</sub> levels were significantly lower (p<0.05) in subjects (6.06±1.83 ng/L) when compared with the control (7.09±1.78 ng/L). Palanisamy *et al* [48] concluded that thyroid dysfunction is frequent in HIV infection and that with progression of disease there is a primary hypothyroid like stage that occurs in patients with HIV infection [49]. Therefore, free T<sub>3</sub>, free T<sub>4</sub> and serum TSH can be used as a surrogate marker of progression of the disease. Thongam *et al* [32]

reported that thyroid dysfunction may be a marker of severity or progression of HIV. In a study by Panamonta *et al.*, [50] 14% of Thai children with HIV had low serum T<sub>3</sub> and normal TSH, and FT<sub>4</sub> levels consistent with sick-euthyroid and all were clinically euthyroid.

The cause of thyroid dysfunction is unclear, but hypotheses include autoimmune disease, concurrent infections, destruction by opportunistic infections, and drug reactions [51]. Thyroid abnormalities are associated with disease progression, including severe immunosuppression and high viral load [52, 53]. Serum levels of TBG progressively increase with the progression of the disease [54, 55]. The reason for the increase in TBG is unknown but seems unrelated to serum estrogen levels or clearance of the protein [56].

On the duration of HAART, the results showed a significant non-increase in TSH ( $p > 0.05$ ) in subjects who had been on drugs within 11-15 years, when compared with subjects who have been on drugs for a period of 0-5 months, 1-5 years, 6-10 years and 16-20 years. T<sub>3</sub> levels were higher ( $p > 0.05$ ) in subjects who had been on drugs within 16-20 years, when compared with subjects who have been on drugs for a period of 0-5 months, 1-5 years, 6-10 years and 11-15 years. T<sub>4</sub> levels were higher ( $p > 0.05$ ) in subjects who had been on drugs within 16-20 years, when compared with subjects who have been on drugs for a period of 0-5 months, 1-5 years, 6-10 years and 11-15 years. A previous study ascribed the elevated levels of thyroid autoantibodies to some non-specific consequences of increased B-cell activation seen in the clinical course of HIV infection as opposed to the Immune Reconstitution syndrome [57].

During HIV infection abnormalities in thyroid include both pathological changes and disturbances in its function [6, 53]. Our present study shows that thyroid dysfunction is frequent in HIV infection and with progression of disease there is a subclinical hypothyroid like stage that occurs in patients with advancing HIV infection [58]. Various thyroid function tests such as FT<sub>3</sub>/FT<sub>4</sub> /serum TSH can be used as a surrogate marker as these correlate with the progression of the disease. One should not start upon the replacement therapy for hypothyroid like state in HIV infection, as the state may be responsive to highly active antiretroviral therapy. Our present study may give the true picture of thyroid abnormality in HIV-AIDS patients. To conclude, abnormal TFTs are encountered often in HIV infection and AIDS patient's individuals. Management guidelines exist for overt dysfunction as described above. However, larger studies are needed to evaluate the prevalence and outcomes of mild thyroid dysfunction in HIV-infected patients and to formulate screening and treatment guidelines.

Thyroid function testing is appropriate for the diagnoses of thyroid disorders in patients with thyroid-related symptoms or with nonspecific systemic symptoms. However, thyroid function screening of asymptomatic individuals is an area of controversy, both for HIV-infected patients and for the general population. Regardless of HIV status, screening of older patients may be justified by the high prevalence of subclinical hypothyroidism and by the potential benefit of levothyroxine therapy in this population [59]. Although cross-sectional studies have reported a higher prevalence of subclinical hypothyroidism than normally observed in the general population, the pathophysiology of subclinical hypothyroidism may differ in HIV-infected patients; at this point, there is insufficient evidence to support routine screening of all HIV-infected individuals. Similarly, although common, the finding of an isolated low FT<sub>4</sub> level has unclear consequences and should not be the target of routine screening.

Measurement of the TSH level is appropriate for patients with symptoms suggestive of thyroid dysfunction, reduced bone mineral density, dyslipidemia, depression, or atrial fibrillation. The finding of an elevated TSH level should prompt the health care provider to measure the FT<sub>4</sub> level, whereas both the FT<sub>4</sub> level and the T<sub>3</sub> level should be measured in patients with a low TSH level (to rule out T<sub>3</sub> toxicosis). When testing

is performed, nonthyroidal illness should be considered in the differential diagnosis of abnormal thyroid function test results, particularly for patients with advanced AIDS or uncontrolled HIV infection.

Stress of advanced disease or concomitant morbidities may manifest as the classic sick euthyroid syndrome probably due to hypothalamic-pituitary deficit related to the progress of immunodeficiency and cachexia [60]. Stavudine used for treatment of HIV infection may impair thyroid function but as the number of patients on this drug is limited this association cannot be established in the present study.

## **5. CONCLUSION**

Abnormal thyroid function test results are common among HIV-infected individuals. This is especially true during HAART, when Graves' disease may be triggered by immune reconstitution and the presence of subclinical hypothyroidism, and when isolated low FT4 levels appear to be more common. Currently, there is insufficient evidence in favor of screening for thyroid abnormalities among asymptomatic HIV-infected individuals. In conclusion, this study highlights that TSH levels were significantly higher ( $p < 0.05$ ) in subjects when compared with the control, and T<sub>4</sub> levels were significantly lower ( $p < 0.05$ ) in subjects when compared with the control.

We hereby recommend the following;

- i. Larger studies are needed to examine the epidemiology and health consequences of mild thyroid dysfunction in HIV-infected subjects and to better inform screening and treatment guidelines.
- ii. Routine screening of the thyroid profile should be included in the treatment plan of HIV subjects.

## **CONSENT**

Only already diagnosed and confirmed HIV positive subjects and apparently healthy subjects who had no known medical condition were recruited for this study. This study specifically included only subjects between 18-50 years who gave consent for the study.

Individuals who are not within the age range of 18-50 years whose HIV status has not been confirmed were excluded. Control subjects who show any sign of visible ailments, would not give consent and have any underlying illness such as diabetes, cardiovascular, sickle cell, pregnant and renal diseases were also excluded from this study.

## **ETHICAL APPROVAL**

Ethical permission for this study was obtained from the Edo State Hospital Management Board, Benin City, Edo State, Nigeria. Informed consent was obtained from the patients prior to the collection of samples for this study. The purpose of the study was exhaustively explained to the patients and assured of the confidentiality of the information obtained from them.

## **COMPETING INTERESTS DISCLAIMER:**

Authors have declared that they have no known competing financial interests OR non-financial interests OR personal relationships that could have appeared to influence the work reported in this paper.

## REFERENCES

1. Cheesbrough, M. (2006). Medical Laboratory Manual for Tropical Countries. Pp. 52 - 55.
2. Park, K. (2019). Surface infection. Park' textbook of preventive and social medicine 25<sup>th</sup> ed. India: Bhanot publishers; p. 371.
3. UNAIDS (2019). Fact sheet: Global HIV & AIDS statistics, 2019. Available at <http://www.unaids.org>. Accessed 01 June 2022.
4. Lambert, M., Zech, F., De Nayer, P., Jamez, J. & Vandercam, B. (2010). Elevation of serum thyroxine-binding globulin (but not cortisol-binding globulin and sex hormone-binding globulin) associated with the progression of human immunodeficiency virus infection. *American Journal of Medicine*, **89**, 748-751.
5. Feldt-Rasmussen, U., Sestoft, L. & Berg, H. (2011). Thyroid function tests in patients with acquired immune deficiency syndrome and healthy HIV I- positive outpatients. *European Journal of Clinical Investigations*, **21**, 59-63.
6. Jain, G., Devpura, G. & Gupta, B.S. (2019). Abnormalities in the Thyroid Function Tests as Surrogate Marker of Advancing HIV Infection in Infected Adults. *Journal of the Association of Physicians of India*, **57**, 508-510.
7. Sanders, J.P., Van Der, G.S. & Kaptein, E. (2017). Characterization of a propylthiouracil insensitive type I iodothyronine deiodinase. *Endocrinology*, **138**, 5153-5160.
8. Malik, R. & Hodgson, H. (2012). The Relationship between the Thyroid Gland and the Liver. *Quarterly Journal of Medicine*, **95**, 559-569.
9. Werner, J. & Ingbar's, U. (2019). The Thyroid: A Fundamental and Clinical Text, Volume 549 edited by Sidney C. Werner, Sidney H. Ingbar, Lewis E. Braverman, Robert D. Utiger. Pp. 45-61.
10. Bal, C. & Chawla, M. (2010). Hyperthyroidism and Jaundice. *Indian Journal of Nuclear Medicine: IJNM: The Official Journal of the Society of Nuclear Medicine, India*, **25**(4), 131-134.
11. WHO/UNAIDS (2019). Global summary of the HIV/AIDS epidemic. December 2019. [www.unaids.org](http://www.unaids.org). Accessed 01 June 2022.
12. Federal Ministry of Health, Nigeria (FMOH) (2010). National Guidelines for Paediatric HIV and AIDS treatment and care. Abuja, Nigeria, Retrieved 25-09-2023.
13. Mulligan, K., Grunfeld, C., Tai, V.W., Algren, H., Pang, M., Chernoff, D.N., Lo, J.C. & Schambelan, M. (2010). Hyperlipidemia and insulin are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. *Journal of Acquired ImmunoDeficiency Syndrome*, **23**, 35-43.
14. Roula, B.Q., Fisher, E., Rublein, J. & Wohl, D.A. (2010). HIV-Associated Lipodystrophy Syndrome. *Pharmacotherapy*, **20**(1), 13-22.
15. Currier, J.S. (2012). Cardiovascular risk associated with HIV therapy. *Journal of Acquired ImmunoDeficiency Syndrome*, **31**, S16-S23.
16. Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G.R., Chisholm, D.J. & Cooper, D.A. (2019). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. *Lancet*, **353**, 2093-2099.
17. Miserez, A.R., Muller, P.Y. & Spaniol, V. (2012). Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. *Acquired Immune Deficiency Syndrome*, **16**(12), 1587-1594.
18. Vigano, A., Mora, S., Testolin, C., Beccio, S., Schneider, L., Bricalli, D., Vanzulli, A., Manzoni, P. & Brambilla, P. (2013). Increased lipodystrophy is associated with increased exposure to highly

- active antiretroviral therapy in HIV-infected children. *Journal of Acquired Immunodeficiency Syndrome*, **32**(5), 482-489.
19. Clotet, B., van der Valk, M., Negredo, E. & Reiss, P. (2013). Impact of nevirapine on lipid metabolism. *Journal of Acquired Immunodeficiency Syndrome*, **34**(1), S79-84.
  20. Palacios, R., Santos, J., García, A., Castells, E., González, M., Ruiz, J. & Márquez, M. (2016). Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. *Human Immunodeficiency Virus Medicine*, **7**(1), 10-15.
  21. Souba, M. & Smith, H. (2016). Thyroid Hormones and Immune Function. *African Journal Online*, **32**, 100–106.
  22. Amadi, K., Sabo, A., Ogunkeye, O. & Oluwole, F. (2018). Thyroid hormone: prime suspect in Human Immunodeficiency Virus Patients? *Nigeria Journal of Physiological Sciences*, **23**, 61–66.
  23. Abbiyesuku, F., Osuji, K., Kuti, M. & Atiba, A. (2014). Thyroid Function Tests in Nigerian HIV Sero-Positive Patients on Highly Active Antiretroviral Therapy (HAART). *International Journal of Medicine and Clinical Research*, **5**, 277–281.
  24. Unachukwu, C., Uchenna, D. & Young, E. (2019). Endocrine and Metabolic Disorders Associated with Human Immunodeficiency Virus Infection. *West African Journal of Medicine*, **28**, 293–299.
  25. Chopra, I.J. (2017). Euthyroid sick syndrome: Is it a misnomer? *Journal of Clinical Endocrinology and Metabolism*, **82**, 329.
  26. Hoffmann, C. J. & Brown, T. T. (2007). Thyroid function abnormalities in HIV-infected patients. *Clinical Infectious Diseases*, **45**(4), 488–494.
  27. Beltran, S., Lescure, F.X. & Desailoud, R. (2013). Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening. *Clinical Infectious Diseases*, **37**(4), 579–583.
  28. Madeddu, G., Spanut, A., Chessat, F. & Galia, G. (2016). Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study. *Clinical Endocrinology*, **64**, 375-383.
  29. Sellmeyer, D.E. & Grunfeld, C. (2016). Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. *Endocrine Reviews*, **17**(5), 518–532.
  30. Dobs, A.S., Dempsey, M.A., Ladenson, P.W. & Polk, B.F. (2018). Endocrine disorders in men infected with the human immunodeficiency virus. *Journal of American Medical Association*, **84**, 611-616.
  31. Calza, L., Manfredi, R. & Chiodo, F. (2002). Subclinical hypothyroidism in HIV-infected patients receiving highly active antiretroviral therapy. *Journal of Acquired Immune Deficiency Syndromes*, **31**(3), 361–363.
  32. Thongam, S., Keithelakpam, S., Singh, T.Y., Singh, R. L., Singh, A. M. & Ranabir, S. (2015). Thyroid dysfunction in human immunodeficiency virus-infected children and its correlation with CD4+ T lymphocyte count. *Indian Journal of Endocrinology and Metabolism*, **19**(2), 272–276.
  33. Goddard, G.Z. & Shoenfeld, Y. (2002). HIV and autoimmunity: *Autoimmunity Reviews*, **1**, 329-337.
  34. Grunfeld, C., Pang, M. & Doerrler, W. (2013). Indices of thyroid function and weight loss in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. *Metabolism*, **42**, 1270-1276.

35. Davidson, M.B. & Chopra, D. (2019). Effect of carbohydrate and non-carbohydrate sources of calories on plasma T3 concentrations in man. *Journal of Clinical Endocrinology and Metabolism*, **48**, 577.
36. Peeters, R.P., Wouters, P.J. & Kaptein, E. (2013). Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. *Journal of Clinical Endocrinology and Metabolism*, **88**, 33202.
37. Chopra, I.J., Chua Teco, G.N. & Mead, J.F. (2015). Relationships between serum free fatty acids and thyroid binding inhibitor in nonthyroidal illness. *Journal of Clinical Endocrinology and Metabolism*, **60**, 980.
38. Chopra, I.J., Huang, T.S. & Beredo, A. (2015). Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3'triiodothyronine in sera of patients with nonthyroidal illness. *Journal of Clinical Endocrinology and Metabolism*, **60**, 666.
39. World Gazetteer (2007). Population of Cities, news, divisions. <http://worldgazetteer.com/ng.php>. Retrieved on 23/05/2022.
40. Onovo, A.A., Adeyemi, A., Onime, D., Kalnoky, M., Kagniniwa, B., Dessie, M., Lee, L., Parrish, D., Adebobola, B., Ashefor, G., Ogorry, O., Goldstein, R. & Meric, H. (2023). Estimation of HIV prevalence and burden in Nigeria: a Bayesian predictive modelling study. *eClinical Medicine*, **62**(102098), 1-15.
41. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771 (<https://hdl.handle.net/10665/325771>). WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
42. Kuritzkes, D.R. & Walker, B.D. (2017). "HIV-1 pathogenesis, clinical manifestations and treatment," in *Fields Virology*, D. M. Knipe and P. M. Howley, Eds., pp. 2187–2214, Williams & Wilkins, Philadelphia, Pa, USA.
43. Wiersinga, W.M. (2014). "Thyroid hormone replacement therapy". *Hormone Research*, **56** (1), 74–81.
44. Shukla, S.K., Singh, G., Ahmad, S., & Pant, P. (2018). Infections, genetic and environmental factors in pathogenesis of autoimmune thyroid diseases. *Microb. Pathog.*, **116**, 279–288.
45. Michèle G., Piroth, L., Verges, B., Sgro, C., Mack, G. & Buisson, M. (2000). Increased prevalence of subclinical hypothyroidism in HIV patients treated with highly active antiretroviral therapy. *AIDS*, **14**(8), 1070.
46. Quirino, T., Bongiovanni, M., Ricci, E., Chebat, E., Carradori, S. & Martinelli, C. (2014). Hypothyroidism in HIV-Infected Patients Who Have or Have Not Received HAART. *Clinical Infectious Diseases*, **38**(4), 596–597.
47. Ji, S., Jin, C., Höxtermann, S., Fuchs, W., Xie, T. & Lu, X. (2016). Prevalence and Influencing Factors of Thyroid Dysfunction in HIV-Infected Patients. *Biomedical Research International*, **2016**, 3874257.
48. Palanisamy, P., Perisamy, M., Uma, M., & Mathiyalagan, D. (2010). Thyroid function, cardiac risk assessment profile and haematological changes during HIV infection and AIDS patients. *J Medicine*, **11**(2), 131-136.
49. Pasupathi, P., Manivannan, P., Manivannan, U. & Deepa, M. (2010). Thyroid function, cardiac risk assessment profile and hematological changes during HIV infection and AIDS patients. *Journal of Medicine*, **11**(2), 131-136.
50. Panamonta, O., Kosalaraksa, P., Thinkhamrop, B., Kirdpon, W., Ingchanin, C. & Lumbiganon, P. (2014). Endocrine function in thai children infected with human immunodeficiency virus. *Journal of Paediatrics and Endocrinology Metabolism*, **17**, 33-40.

51. Viganò, A., Riboni, S., Bianchi, R., Cafarelli, L., Vago, T. & Manzoni, P. (2014). Thyroid dysfunction in antiretroviral treated children. *Paediatric Infectious Disease Journal*, **23**, 235-239.
52. Hirschfeld, S., Laue, L., Cutler, G.B. Jr. & Pizzo, P.A. (2016). Thyroid abnormalities in children infected with human immunodeficiency virus. *Journal of Paediatrics*, **128**, 70-74.
53. Chiarelli, F., Galli, L., Verrotti, A., di Ricco, L., Vierucci, A. & de Martino, M. (2020). Thyroid function in children with perinatal human immunodeficiency virus type 1 infection. *Thyroid*, **10**, 499-505.
54. Lambert, M. (2014). Thyroid dysfunction in HIV infection. *Baillieres Clinical Endocrinology Metabolism*, **8**, 825-835.
55. LoPresti, J.S., Fried, J.C., Spencer, C.A. & Nicoloff, J.T. (2019). Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS). *Annals of Internal Medicine*, **110**, 970-975.
56. Weetman, A.P. (2014). Thyroid abnormalities. *Endocrinology Metabolism in Clinics in North American*, **43**, 781-790.
57. Lane, H.C., Masur, H., Edgar, L.C., Whalen, G., Rook, A.H. & Fauci, A.S. (2019). Abnormalities of B-Cell Activation and Immunoregulation in Patients with the acquired immunodeficiency syndrome. *New England Journal of Medicine*, **309**(8), 453-458.
58. Bongiovanni, M., Adorni, F. & Casana, M. (2016). Subclinical hypothyroidism in HIV-infected subjects. *Journal of Antimicrobial and Chemotherapy*, **58**, 1086-1089.
59. Surks, M.I., Ortiz, E. & Daniels, G.H. (2014). Subclinical thyroid disease. *Journal of American Medical Association*, **291**, 228-238.
60. Tang, W.W. & Kaptein, E.M. (2019). Thyroid hormone levels in the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. *West Journal of Medicine*, **151**, 627-631.